Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.71%. A quarter ago, it was expected that this company would post a loss of $0.89 per share when it actually produced a loss of $0.90, delivering a surprise of -1.12%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CRINETICS PHARMACEUTICALS, INC. QUARTERLY REPORT ON FORM 10-Q For the Quarter Ended March 31, 2024 | --- | --- | |----------|-------| | | | | | | | | | | Item 1. | | | Item 1A. | | | Item 2. | | | | | | Item 3. | | | Item 4. | | | Item 5. | | | Item 6. | | Item 1. Condensed Financial Statemen ...

Crinetics Pharmaceuticals’ (CRNX) shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants w ...

Crinetics Pharmaceuticals, Inc. (CRNX) shares ended the last trading session 19.1% higher at $45.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.3% gain over the past four weeks.The sudden surge in the stock price was observed after Crinetics reported achieving primary and all key secondary endpoints, with statistical significance, in the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy a ...

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a Conference Call Today at 8:30 a.m. Eastern Time SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel t ...

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Previously Reported Management to Host a Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the ...

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material to th ...

koya79 Financial and Clinical Progress Positions Crinetics for Market Leadership Much has changed at Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) since my first look nearly a year ago. Back then, I expressed concern over their oral solution for acromegaly and made the argument that paltusotine, by the nature of its oral administration, would likely not be able to replicate the efficacy and safety of existing subcutaneous drugs like octreotide. Nonetheless, I did recognize the potential of Crinetics' dr ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive Officer Alan Krasner - Chief Endocrinologist Marc Wilson - Chief Financial Officer Jim Hassard - Chief Commercial Officer Conference Call Participants Joseph Schwartz - Leerink Partners Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Cory Jubinville - LifeSci Brian Skorney - Baird Douglas Tsao - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other juris ...